TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17713335

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (MFP; 1,450 ppm F) dentifrice
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF; 1,450 ppm F) dentifrice
Number of subjects: 296

Group type: COMPARATOR
Intervention: Herbal, non-fluoride placebo dentifrice
Number of subjects: 296
Study: 12796224

Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride or nortriptyline hydrochloride, with or without interpersonal psychotherapy
Number of subjects: 395

Group type: COMPARATOR
Intervention: High-risk patients (recent suicide attempt or current suicidal ideation)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Moderate-risk patients (recurrent thoughts of death)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Low-risk patients (no suicide attempt, suicidal ideation, or thoughts of death)
Number of subjects: 395
Study: 10819854

Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Early pushing
Number of subjects: 1862
Study: 8648369

Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin 135 mg/m2
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin doses >60 mg/m2
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin doses
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters
Number of subjects: 287
Study: 1523876

Group type: EXPERIMENTAL
Intervention: MDP‐virosome vaccine
Number of subjects: 77

Group type: COMPARATOR
Intervention: HA vaccine
Number of subjects: 77
Study: 6150183

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study: 30806038

Group type: EXPERIMENTAL
Intervention: Approach-oriented coping strategies
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Avoidant coping strategies
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Psychological well-being
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Quality of practice environment
Number of subjects: 500
Study: 28010050

Group type: EXPERIMENTAL
Intervention: 1500 mg of intravenous iron isomaltoside
Number of subjects: 13

Group type: COMPARATOR
Intervention: RBC transfusion
Number of subjects: 13
Study: 25966266

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride combined with hemoperfusion
Number of subjects: 61

Group type: COMPARATOR
Intervention: Penehyclidine hydrochloride alone (control group)
Number of subjects: 61
Study: 23808948

Group type: EXPERIMENTAL
Intervention: Cap-assisted water immersion
Number of subjects: 208

Group type: COMPARATOR
Intervention: Water immersion colonoscopy
Number of subjects: 208
Study: 22338233

Group type: EXPERIMENTAL
Intervention: Hybrid bioartificial liver support system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plasma exchange (Control)
Number of subjects: 12
Study: 19803232

Group type: EXPERIMENTAL
Intervention: J in three‐needle therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 180
Study: 16953007

Group type: EXPERIMENTAL
Intervention: Journey of Hope intervention (8 modules of education on mental illness, problem-solving and communication skills training, family support)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 462
Study: 15663103

Group type: EXPERIMENTAL
Intervention: Ganaton (Itopridi hydrochloridum)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10788542

Group type: EXPERIMENTAL
Intervention: CPH 82 300 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg/week
Number of subjects: 100
Study: 9058219

Group type: EXPERIMENTAL
Intervention: Lidoflazine (1 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32
Study: 8473250

Group type: EXPERIMENTAL
Intervention: Active student response error correction
Number of subjects: 6

Group type: COMPARATOR
Intervention: No-response error correction
Number of subjects: 6
Study: 4037714

Group type: EXPERIMENTAL
Intervention: 20 mg of Primperan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31127399

Group type: EXPERIMENTAL
Intervention: Optimized formulation of nifedipine (3.083 mg HPMC K15M, 29.859 mg HPMC E15LV, 3.541 mg Carbopol 974P)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Optimized formulation of nifedipine
Number of subjects: 10
Study: 31240769

Group type: EXPERIMENTAL
Intervention: Overweight condition
Number of subjects: 320

Group type: COMPARATOR
Intervention: Symptom frequency (daily or weekly)
Number of subjects: 320
Study: 28063801

Group type: EXPERIMENTAL
Intervention: mid‐follicular phase recombinant LH (rLH) supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: urinary human chorionic gonadotrophin (uHCG) supplementation
Number of subjects: 49
Study: 25213157

Group type: EXPERIMENTAL
Intervention: Recovery-focused cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 67
Study: 23683793

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day + Guanfacine 1 mg/day (N/G)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day + Guanfacine placebo (N/P)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Naltrexone placebo + Guanfacine (P/G)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Double placebo (P/P)
Number of subjects: 301
Study: 21524239

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 532

Group type: COMPARATOR
Intervention: Dasatinib 100 mg once daily
Number of subjects: 532
Study: 18971892

Group type: EXPERIMENTAL
Intervention: Magnet patch (M)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo patch (P)
Number of subjects: 58
Study: 16153766

Group type: EXPERIMENTAL
Intervention: TiN coating at 200 W
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TiN coating at 500 W
Number of subjects: 4

Group type: COMPARATOR
Intervention: Non-coated group without metal conditioner
Number of subjects: 4

Group type: COMPARATOR
Intervention: Non-coated group with metal conditioner
Number of subjects: 4
Study: 14971864

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 384
Study: 11002408

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA; Tiobec) 600 mg per day for 20 days followed by 200 mg per day for 10 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cellulose starch 100 mg per day as placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) after switching from placebo
Number of subjects: 42
Study: 9216279

Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluid (W‐i.v.f.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Room temperature intravenous fluid (RT‐i.v.f.)
Number of subjects: 30
Study: 8484502

Group type: EXPERIMENTAL
Intervention: Ephedrine infusion (5 mg/min for the first 2 min, then 1 mg/min for the next 18 min)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Crystalloid administration (15 mL/kg)
Number of subjects: 54
Study: 3438130

Group type: EXPERIMENTAL
Intervention: EMG-Biofeedback
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EMG-only group
Number of subjects: 42
Study: 30107070

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83
Study: 28187920

Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged monitoring (10-day Holter-ECG monitoring at baseline, and at 3 months and 6 months)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard care procedures (at least 24 hours of rhythm monitoring)
Number of subjects: 398
Study: 25627795

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 201
Study: 23901264

Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN‐α (3 million IU) 3 times per week (group B)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN‐γ (3 million IU) 3 times per week (group C)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN‐α and IFN‐γ (1.5 million IU of each) 3 times per week (group D)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 164
Study: 21908960

Group type: EXPERIMENTAL
Intervention: Suction drain used (Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No suction drain used (Group A)
Number of subjects: 72
Study: 17503182

Group type: EXPERIMENTAL
Intervention: Imipramine (50 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16683433

Group type: EXPERIMENTAL
Intervention: Orion plate system
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Zephir plate system
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Codman plate system
Number of subjects: 122
Study: 14610048

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 28 days for 2 years)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: CMF (six 28-day cycles)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 1010
Study: 10921358

Group type: EXPERIMENTAL
Intervention: High-altitude (4300 m)
Number of subjects: 228
Study: 7782031

Group type: EXPERIMENTAL
Intervention: Recombinant a2 interferon (Roferon) 6 MU x 7 days every 3 weeks, Adriamycin 60 mg/m2 i.v. once every 3 weeks, Tamoxifen 10 mg p.o. twice daily continuously, Desferrioxamine 500 mg i.m. daily x 7 days every 3 weeks, Ascorbic acid 300 mg p.o. daily 1 hour after DFO x 7 days every 3 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 7
Study: 2236463

Group type: EXPERIMENTAL
Intervention: Lithium carbonate maintenance doses (600 mg to 1,500 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Saliva lithium levels
Number of subjects: 30
Study: 346191

Group type: EXPERIMENTAL
Intervention: Fluorescent antibody method for detection of estrogen receptors
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dextran-coated charcoal and sucrose gradient assay techniques
Number of subjects: 106
Study: 30109474

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/Quinidine (DM/Q)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30522086

Group type: EXPERIMENTAL
Intervention: Invasive angiography (or computed tomography angiography as per local preference) within 5 days of randomization
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Conservative management (with or without functional testing at clinician discretion)
Number of subjects: 1800
Study: 28212135

Group type: EXPERIMENTAL
Intervention: Intrastent thrombus less than 16%
Number of subjects: 128

Group type: COMPARATOR
Intervention: Intrastent thrombus at least 16%
Number of subjects: 128
Study: 25960116

Group type: EXPERIMENTAL
Intervention: PFJ-targeted exercise, education, manual-therapy and taping program
Number of subjects: 92

Group type: COMPARATOR
Intervention: OA-education (control condition)
Number of subjects: 92
Study: 23275098

Group type: EXPERIMENTAL
Intervention: Modified food frequency questionnaire (FFQ)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 3-day food record (3DFR)
Number of subjects: 29
Study: 21619909

Group type: EXPERIMENTAL
Intervention: PCV13+TIV
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo+TIV
Number of subjects: 1160
Study: 18059398

Group type: EXPERIMENTAL
Intervention: Hospital communication
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Direct mail communication
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Letter with telephone number
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Direct from trials office
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Lay terms for results
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Next of kin receiving results
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Next of kin not receiving results
Number of subjects: 1431
Study: 16468060

Group type: EXPERIMENTAL
Intervention: LITE (40% of maximal oxygen consumption)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: MOD (60% of maximal oxygen consumption)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 47
Study: 12956742

Group type: EXPERIMENTAL
Intervention: Non-bronchoscopic bronchial brushing
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (adults undergoing standard bronchoscopic sampling)
Number of subjects: 63
Study: 11022987

Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg vs 800 microg)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 267
Study: 9433608

Group type: EXPERIMENTAL
Intervention: Robust multipoint genome scans for linkage using a dense marker map
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lod‐score likelihood analyses in full pedigrees and affected relative families
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence from more than one method
Number of subjects: 0
Study: 8519374

Group type: EXPERIMENTAL
Intervention: Budesonide (600 micrograms.day-1) plus salbutamol (600 micrograms.day-1) (BA+CS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Salbutamol plus placebo (BA+PL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Budesonide (600 micrograms.day-1) plus salbutamol (600 micrograms.day-1) (BA+CS) after switching from BA+PL
Number of subjects: 55
Study: 3507007

Group type: EXPERIMENTAL
Intervention: Beef extended with soy isolate, soy concentrate, or soy flour (20% reconstituted soy product, 80% beef)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Beef extended with soy products fortified with 60 mg Fe and 25 mg Zn/100 g protein
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group consuming usual self-selected diets
Number of subjects: 245
Study: 30015405

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1148
Study: 26784110

Group type: EXPERIMENTAL
Intervention: Exposure to four types of physical IPV in the past year
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Lagged IPV intensity
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Fixed effects regression model accounting for time-invariant confounding
Number of subjects: 1238
Study: 24057079

Group type: EXPERIMENTAL
Intervention: Triple therapy (group I) with 1 intravaginal ovule containing 30 mcg estriol and Lactobacilli acidophili (50 mg lyophilisate containing at least 100 million live bacteria) once daily for 2 weeks, then two ovules once weekly for a total of 6 months plus pelvic floor rehabilitation.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intravaginal estriol ovule (1 mg) plus pelvic floor rehabilitation (group II).
Number of subjects: 136
Study: 23247908

Group type: EXPERIMENTAL
Intervention: Crushed IRO‐A (15 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crushed IRO (15 mg)
Number of subjects: 40
Study: 20545406

Group type: EXPERIMENTAL
Intervention: Project Support
Number of subjects: 35

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 35
Study: 18337057

Group type: EXPERIMENTAL
Intervention: Full effort instruction
Number of subjects: 73

Group type: COMPARATOR
Intervention: Malingering scenario instruction
Number of subjects: 73
Study: 16299090

Group type: EXPERIMENTAL
Intervention: Multicomponent prevention campaign including educational brochures and media broadcasts
Number of subjects: 237

Group type: COMPARATOR
Intervention: Comparison with non-eye injury rates
Number of subjects: 237
Study: 12455823

Group type: EXPERIMENTAL
Intervention: Pool exercise therapy and education
Number of subjects: 26
Study: 11270999

Group type: EXPERIMENTAL
Intervention: Domestic 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Imported 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both domestic and imported capsules
Number of subjects: 20
Study: 8889077

Group type: EXPERIMENTAL
Intervention: Community residence label with disturbed behaviour
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Psychiatric hospital label with disturbed behaviour
Number of subjects: 488

Group type: COMPARATOR
Intervention: Community residence label with control behaviour
Number of subjects: 488

Group type: COMPARATOR
Intervention: Psychiatric hospital label with control behaviour
Number of subjects: 488
Study: 1478035

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg three times daily for 3 months)
Number of subjects: 30
Study: 6363219

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31691531

Group type: COMPARATOR
Intervention: IBT‐alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IBT‐liraglutide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Multicomponent (IBT-liraglutide + portion-controlled diet)
Number of subjects: 150
Study: 29506562

Group type: EXPERIMENTAL
Intervention: BetaMe programme (comprehensive self-management programme delivered by mobile and web-based technologies)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430
Study: 26599983

Group type: EXPERIMENTAL
Intervention: Nonselective β-blockers (NSBBs)
Number of subjects: 1198
Study: 24943829

Group type: EXPERIMENTAL
Intervention: Climate Schools program (six lesson computer‐based program)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Usual health classes including drug education
Number of subjects: 1734
Study: 22770996

Group type: EXPERIMENTAL
Intervention: High body checking group (focus on typically disliked body parts)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Low body checking group (focus on bodies as a whole with neutral terms)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: High body checking group
Number of subjects: 234

Group type: COMPARATOR
Intervention: Low body checking group
Number of subjects: 234
Study: 20220611

Group type: EXPERIMENTAL
Intervention: Yoga exercise program (3 times per week for 70 minutes per session over 24 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 69
Study: 17451612

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy/meditation intervention (4 one-hour sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waiting list control (3 months before receiving treatment)
Number of subjects: 25
Study: 16463837

Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide 50%/fentanyl (n = 22)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl/air/oxygen (n = 26)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prone position (n = 23)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Supine position (n = 25)
Number of subjects: 48
Study: 12424105

Group type: EXPERIMENTAL
Intervention: Intravenous 2 mg/kg of [13C]Phe
Number of subjects: 18
Study: 10503580

Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study: 8696702

Group type: EXPERIMENTAL
Intervention: Automatic Exposure Control (AEC) technique
Number of subjects: 329

Group type: COMPARATOR
Intervention: Manual Exposure Control (MEC) technique
Number of subjects: 329
Study: 1714885

Group type: EXPERIMENTAL
Intervention: Flecainide 150 mg twice daily
Number of subjects: 24
Study: 6110863

Group type: EXPERIMENTAL
Intervention: mannitol
Number of subjects: 20

Group type: COMPARATOR
Intervention: castor oil
Number of subjects: 20
Study: 30875313

Group type: COMPARATOR
Intervention: NP (no cavity preparation, control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOD3 (3.0-mm-deep MOD preparation, not restored)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOD3R (3.0-mm-deep MOD preparation restored with RBC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOD5 (5.0-mm-deep MOD preparation, not restored)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOD5R (5.0-mm-deep MOD preparation restored with RBC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOD3RC (3.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOD5RC (5.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Number of subjects: 70
Study: 29191194

Group type: EXPERIMENTAL
Intervention: Herbal medicine (HM) services utilization
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Reasons for using HM
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Disclosure of HM use
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Socio-economic status influence on HM use
Number of subjects: 500
Study: 27614789

Group type: EXPERIMENTAL
Intervention: Intralipid (2mL diluted at 20% in 250mL saline) infusion
Number of subjects: 296

Group type: COMPARATOR
Intervention: Saline (250mL) infusion
Number of subjects: 296
Study: 24856748

Group type: EXPERIMENTAL
Intervention: Blood pressure cuff (inflated to 150 mm Hg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 38
Study: 22562540

Group type: EXPERIMENTAL
Intervention: 10% lidocaine topical spray
Number of subjects: 129

Group type: COMPARATOR
Intervention: Distilled water topical spray
Number of subjects: 129